Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo ...
Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...
Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...
An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...
The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented ...
fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapse Basel, 28 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
“Building on Columvi’s established benefits, [this] data demonstrate[s] the potential of this combination regimen to improve ... into the first-line DLBCL setting. To that end, Roche is ...
– Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009 (Tambiciclib) in r/r AML – Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – ...
Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback